C4 Therapeutics Inc (CCCC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$3.44-3.10%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
C4 Therapeutics has a strong partnership with Roche. It aims to fund operations through 2028. The company recently beat earnings twice. Its stock rose 5% in one day.
C4 is still losing money and revenue is expected to drop 33%. The CFO recently left. The company has no clear revenue or profit guidance.
The stock trades about 19% above our fair value near $3.60. Analysts expect revenue to fall about 33% next year. Our view sees some recovery but risks remain.
Breaks if: EPS loss worsens or fails to improve by 10% in FY27
Breaks if: Cash reserves fall below levels needed to fund operations through 2028
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. CCCC is currently loss-making but is advancing key therapies and partnerships, which could drive future growth.
The market appears to have low expectations for CCCC, as indicated by a valuation that is aligned with peers but still reflects a significant expectations gap. The current pricing does not seem to account for potential upside from successful product developments.
Management is focused on advancing cemsidomide and expanding its partnership with Roche, which could support revenue growth. However, the company is still loss-making, and recent financial performance has been neutral compared to its industry peers.
The long-term thesis hinges on the success of CCCC's clinical trials and partnerships, as well as broader sector performance. Key risks include potential guidance cuts and economic conditions that could affect demand in the healthcare sector.
The most important moves since the prior daily snapshot.
Company momentum rose by 29.7 points (from 10.0 to 39.7).
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Ensure current cash, cash equivalents, and marketable securities fund operations to the end of 2028.
Breaks if: Revenue declines more than 10% in FY27
Breaks if: Partnership with Roche ends or fails to advance drug candidates
Collaborate with Roche on the discovery, development, and commercialization of degrader-antibody conjugates.
Over the next 1 to 3 years, CCCC's performance will depend on its ability to execute on its strategic priorities and navigate market challenges. Not investment advice.